Abstract
AbstractPharmacological and dietary approaches to reducing high blood lipids in the general population decrease cardiovascular disease risk. Patients with chronic kidney disease (CKD) often display elevated blood lipids, and reducing cholesterol levels with statin drugs reduces cardiovascular disease in patients with moderate CKD, similar to the effects in the general population. Benefits to kidney disease itself appear to be marginal, if present. Studies with omega‐3 fatty acids indicate that both cardiovascular and kidney disease progression may be slowed by dietary omega‐3 fatty acids in CKD patients, but long‐term studies are needed to confirm these findings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
